Requirement of androgen-dependent activation of protein kinase Cζ for androgen-dependent cell proliferation in LNCaP cells and its roles in transition to androgen-independent cells

Molecular Endocrinology

Volumn 20, Issue 12, 2006, Pages 3053-3069

  Inoue, Takahiro ^a   Yoshida, Toru ^a   Shimizu, Yosuke ^a   Kobayashi, Takashi ^a   Yamasaki, Toshinari ^a   Toda, Yoshinobu ^a   Segawa, Takehiko ^a   Kamoto, Toshiyuki ^a   Nakamura, Eijiro ^a   Ogawa, Osamu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE C; RAPAMYCIN; S6 KINASE;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL SURVIVAL; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HORMONAL REGULATION; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANDROGENS; CELL LINE; CELL PROLIFERATION; CULTURE MEDIA; ENZYME ACTIVATION; HUMANS; KI-67 ANTIGEN; MALE; PROSTATIC NEOPLASMS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIROLIMUS; TUMOR CELLS, CULTURED;

MAMMALIA;

EID: 33751501696     PISSN: 08888809     EISSN: 08888809     Source Type: Journal    
DOI: 10.1210/me.2006-0033     Document Type: Article

References (66)

1. Huggins C, Hodges CV 1941 Studies on prostatic cancer: effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297
2. Gelmann EP 2002 Molecular biology of the androgen receptor. J Clin Oncol 20:3001-3015
3. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39
4. Feldman BJ, Feldman D 2001 The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45
5. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP 1995 In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401-406
6. Gregory CW, Johnson RT, Mohler JL, French FS, Wilson, EM 2001 Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61:2892-2892
7. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP 1995 Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398
8. Han G, Buchanan G, Ittmann M, Harris JM, Yu X, Demayo FJ, Tilley W, Greenberg NM 2005 Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci USA 102:1151-1156
9. Miyamoto H, Yeh S, Wilding G, Chang C 1998 Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA 95:7379-7384
10. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H 1994 Androgen receptor activation in prostatic tumor cell lines by insulinlike growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474-5478
11. Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D, Miyake H, Gleave ME 2003 Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 63:3575-3584
12. Craft N, Shostak Y, Carey M, Sawyers CL 1999 A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280-285
13. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh JT, Tu SM, Campbell ML 1992 Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944
14. Gleave M, Tolcher A, Miyake, Nelson C, Brown B, Beraldi E, Goldie J 1999 Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 5:2891-2898
15. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP 1983 LNCaP model of human prostatic carcinoma. Cancer Res 4:1809-1818
16. Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I, Shaw N, Prins GS, Kozlowski JM 1995 Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 136:796-803
17. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H 1999 Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 81:242-251
18. Igawa T, Lin FF, Lee MS, Karan D, Batra SK, Lin MF 2002 Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 50:222-235
19. Wang LG, Ossowski L, Ferrari AC 2001 Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line. Cancer Res 61:7544-7551
20. Shi XB, Ma AH, Tepper CG, Xia L, Gregg JP, Gandour-Edwards R, Mack PC, Kung HJ, DeVere White RW 2004 Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate 60:257-271
21. Jacinto E, Hall MN 2003 Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 4:117-126
22. Inoki K, Ouyang H, Li Y, Guan KL 2005 Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev 69:79-100
23. Inoki K, Corradetti MN, Guan KL 2005 Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37:19-24
24. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J 2004 mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24:200-216
25. Lane HA, Fernandez A, Lamb NJ, Thomas G 1993 p70s6k function is essential for G1 progression. Nature 363:170-172
26. Martin KA, Blenis J 2002 Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. Adv Cancer Res 86:1-39
27. Chou MM, Blenis J 1996 The 70 kDa S6 kinase complexes with and is activated by the Rho family G proteins Cdc42 and Rac1. Cell 85:573-583
28. Pullen N, Dennis PB, Andjelkovic M, Dufner A, Kozma SC, Hemmings BA, Thomas G 1998 Phosphorylation and activation of p70s6k by PDK1. Science 279:707-710
29. Romanelli A, Martin KA, Toker A, Blenis J 1999 p70 S6 kinase is regulated by protein kinase C ζ and participates in a phosphoinositide 3-kinase-regulated signalling complex. Mol Cell Biol 19:2921-2928
30. Akimoto K, Nakaya M, Yamanaka T, Tanaka J, Matsuda S, Weng Q, Avruch J, Ohno, S 1998 Atypical protein kinase Clambda binds and regulates p70 S6 kinase. Biochem J 335:417-424
31. Chou MM, Hou W, Johnson J, Graham LK, Lee MH, Chen CS, Newton AC, Schaffhausen BS, Toker A 1998 Regulation of protein kinase C ζ by PI 3-kinase and PDK-1. Curr Biol 8:1069-1077
32. Le Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P, Parker PJ 1998 Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 281:2042-2045
33. Nakanishi H, Exton JH 1992 Purification and characterization of the zeta isoform of protein kinase C from bovine kidney. J Biol Chem 267:16347-16354
34. Parekh DB, Ziegler W, Parker PJ 2000 Multiple pathways control protein kinase C phosphorylation. EMBO J 19:496-503
35. Takeda H, Matozak T, Takada T, Noguchi T, Yamao T, Tsuda M, Ochi F, Fukunaga K, Inagaki K, Kasuga M 1999 PI 3-kinase γ and protein kinase C-ζ mediate RAS-independent activation of MAP kinase by a Gi protein-coupled receptor. EMBO J 18:386-395
36. Scott MT, Ingram A, Ball KL 2002 PDK1-dependent activation of atypical PKC leads to degradation of the p21 tumour modifier protein. EMBO J 21:6771-6780
37. Knudsen KE, Arden KC, Cavenee WK 1998 Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem 273:20213-20222
38. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ 2001 Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 142:4795-4805
39. Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M 2004 Changes in androgen receptor non-genotropic signaling correlates with transition of LNCaP cells to androgen independence. Cancer Res 64:7156-7168
40. Gioeli D, Mandell JW, Petroni GR, Frierson Jr HF, Weber MJ 1999 Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59:279-284
41. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ 2003 Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 63:1981-1989
42. Weng QP, Andrabi K, Kozlowski MT, Grove JR, Avruch J 1995 Multiple independent inputs are required for activation of the p70 S6 kinase. Mol Cell Biol 15:2333-2340
43. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM 1998 RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 95:1432-1437
44. Chung J, Grammer TC, Lemon KP, Kazlauskas A, Blenis J 1994 PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature 370:71-75
45. Sekulic A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM, Abraham RT 2000 A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 60:3504-3513
46. Dan HC, Sun M, Yang L, Feldman RI, Sui XM, Ou CC, Nellist M, Yeung RS, Halley DJ, Nicosia SV, Pledger WJ, Cheng JQ 2002 Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 277:35364-35370
47. Inoki K, Li Y, Zhu T, Wu J, Guan KL 2002 TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4:648-657
48. Ghosh PM, Bedolla R, Mikhailova M, Kreisberg JI 2002 RhoA-dependent murine prostate cancer cell proliferation and apoptosis: role of protein kinase Cζ. Cancer Res 62:2630-2636
49. Inoue T, Segawa T, Shiraishi T, Yoshida T, Toda Y, Yamada T, Kinukawa N, Kinoshita H, Kamoto T, Ogawa O 2005 Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 66:332-337
50. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M 2000 Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 92:1918-1925
51. Gao N, Zhang Z, Jiang BH, Shi X 2003 Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 310:1124-1132
52. Pfeil K, Eder IE, Putz T, Ramoner R, Culig Z, Ueberall F, Bartsch G, Klocker H 2004 Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate 58:259-268
53. Sansal I, Sellers WR 2004 The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22:2954-2963
54. Kokontis JM, Hsu S, Chuu C, Dang M, Fukuchi J, Hiipakka RA, Liao S 2005 Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Prostate 65:287-298
55. Fang L, Li G, Liu G, Lee SW, Aaronson SA 2001 p53 Induction of heparin-binding EGF-like growth factor counteracts p53 growth suppression through activation of MAPK and PI3K/Akt signaling cascades. EMBO J 20:1931-1939
56. Ravi RK, McMahon M, Yangang Z, Williams JR, Dillehay LE, Nelkin BD, Mabry M 1999 Raf-1-induced cell cycle arrest in LNCaP human prostate cancer cells. J Cell Biochem 72:458-469
57. Ghosh PM, Malik SN, Bedolla RG, Wang Y, Mikhailova M, Prihoda TJ, Troyer DA, Kreisberg JI 2005 Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. Endocr Relat Cancer 12:119-134
58. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin Jr WG, Schlisio S 2005 Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8:155-167
59. Hernandez-Pigeon H, Quillet-Mary A, LouatT, Schambourg A, HumbertO, Selves J, Salles B, LaurentG, Lautier D 2005 hMutS α is protected from ubiquitin-proteasome-dependent degradation by atypical protein kinase C ζ phosphorylation. J Mol Biol 348:63-74
60. Geck P, Maffini MV, Szelei J, Sonnenschein C, Soto AM 2000 Androgen-induced proliferative quiescence in prostate cancer cells: the role of AS3 as its mediator. Proc Natl Acad Sci USA 97:10185-10190
61. Soto AM, Sonnenschein C 2001 The two faces of janus: sex steroids as mediators of both cell proliferation and cell death. J Natl Cancer Inst 93:1673-1675
62. Castoria G, Migliaccio A, Di Domenico M, Lombardi M, de Falco A, Varricchio L, Bilancio A, Barone MV, Auricchio F 2004 Role of atypical protein kinase C in estradiol-triggered G1/S progression of MCF-7 cells. Mol Cell Biol 24:7643-7653
63. Heinlein C, Chang C 2002 The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol 18:2181-2187
64. Freeman MR, Cinar B, Lu ML 2005 Membrane rafts as potential sites of nongenomic hormnonal signaling in prostate cancer. Trends Endocrinol Metab 16:273-279
65. Migliaccio A, Castoria G, Di Domenico m, deFalco A, Bilancio A, Lombardi M, Barone MV, Ametrano D, Zannini MS, Abbondanza C, Auricchio F 2000 Sreroid-induced androgen receptor-oestradiol receptor β-Src complex triggers prostate cancer cell proliferation. EMBO J 19:5406-5417
66. Inoue T, Nakanishi H, Inada K, Hioki T, Tatematsu M, Sugimura Y 2001 Real time reverse transcriptase polymerase chain reaction of urinary cytokeratin 20 detects transitional cell carcinoma cells. J Urol 166:2134-2141